viernes, 9 de agosto de 2024
American Society of Clinical Oncology (ASCO) 2024 ++++
https://www.medscape.com/viewcollection/37458?ecd=mkm_ret_240809_mscpmrk_masters_non-att_etid6727227&uac=148436CN&impID=6727227
Unlocking ASCO 2024: Must-Know Breakthroughs
https://www.medscape.com/viewarticle/unlocking-asco-2024-must-know-breakthroughs-2024a1000chj?ecd=mkm_ret_240809_mscpmrk_masters_non-att_etid6727227&uac=148436CN&impID=6727227
'Impressive' 5-Year Progression-Free Survival With Lorlatinib in ALK+ NSCLC
https://www.medscape.com/viewarticle/outstanding-5-year-progression-free-survival-lorlatinib-alk-2024a1000aas?ecd=mkm_ret_240809_mscpmrk_masters_non-att_etid6727227&uac=148436CN&impID=6727227
ESOPEC: FLOT Bests CROSS in Resectable Esophageal Cancer
https://www.medscape.com/viewarticle/esopec-flot-bests-cross-resectable-esophageal-cancer-2024a1000azn?ecd=mkm_ret_240809_mscpmrk_masters_non-att_etid6727227&uac=148436CN&impID=6727227
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario